Baidu
map

Lancet Diab & Endo:荟萃分析显示糖尿病增加肢体残疾风险

2013-07-22 伊文 Lancet

依据先前的报道,由于糖尿病引起残疾的风险从零到双倍不等。残疾是一种重要的衡量健康的指标,且鉴于全球糖尿病的流行,评估糖尿病引起残疾的风险是非常重要的。为此,来自澳大利亚莫纳什大学的Evelyn Wong教授及其团队进行了一项系统性回顾和荟萃分析,评估糖尿病引起残疾的风险。该研究结果在线发表在2013年7月24的《柳叶刀糖尿病与内分泌学》(The Lancet Diab

依据先前的报道,由于糖尿病引起残疾的风险从零到双倍不等。残疾是一种重要的衡量健康的指标,且鉴于全球糖尿病的流行,评估糖尿病引起残疾的风险是非常重要的。为此,来自澳大利亚莫纳什大学的Evelyn Wong教授及其团队进行了一项系统性回顾和荟萃分析,评估糖尿病引起残疾的风险。该研究结果在线发表在2013年7月24的《柳叶刀糖尿病与内分泌学》(The Lancet Diabetes & endocrinology)杂志上。

该研究在2012年8月8日前搜索了Ovid、Medline、荷兰医学文摘数据库、考克兰图书馆和护理及健康文献联合指引。包括在有或没有任何类型糖尿病的人群中,通过测量日常生活活动(ADL)、工具性日常生活活动(IADL)、或移动性,比较残疾风险的成人研究。排除有特殊疾病亚群或养老院人群的研究。从研究中,记录人口特征、糖尿病如何诊断(通过医师或自我报告)、残疾的部位和定义、以及残疾风险评估。通过残疾类型和风险评估类型(比值比[OR]或风险比[RR])计算综合评估。

该研究结果表明,系统性回顾得到3224个结果,其中的26项研究纳入荟萃分析。糖尿病增加移动性残疾(15项研究;OR 1.71,95%CI 1.53–1.91;RR 1.51,95%CI 1.38–1.64)、IADL残疾(10项研究;OR 1.65,95%CI 1.55–1.74)、ADL残疾(16项研究;OR 1.82,95%CI 1.63–2.04;RR 1.82,95%CI 1.40–2.36)的风险。

该研究发现,糖尿病与肢体残疾风险显著增加有关。努力促进健康老龄化应该通过预防和管理糖尿病应对这种风险。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1681253, encodeId=ead61681253f7, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Sep 22 00:54:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636719, encodeId=d3fb1636e191d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 14 21:54:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827597, encodeId=d01f182e5971d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 14 16:54:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808468, encodeId=806b180846802, content=<a href='/topic/show?id=31f281840d6' target=_blank style='color:#2F92EE;'>#肢体残疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81840, encryptionId=31f281840d6, topicName=肢体残疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Sep 29 15:54:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836843, encodeId=d2dc183684321, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Fri Apr 11 12:54:00 CST 2014, time=2014-04-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1681253, encodeId=ead61681253f7, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Sep 22 00:54:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636719, encodeId=d3fb1636e191d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 14 21:54:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827597, encodeId=d01f182e5971d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 14 16:54:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808468, encodeId=806b180846802, content=<a href='/topic/show?id=31f281840d6' target=_blank style='color:#2F92EE;'>#肢体残疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81840, encryptionId=31f281840d6, topicName=肢体残疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Sep 29 15:54:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836843, encodeId=d2dc183684321, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Fri Apr 11 12:54:00 CST 2014, time=2014-04-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1681253, encodeId=ead61681253f7, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Sep 22 00:54:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636719, encodeId=d3fb1636e191d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 14 21:54:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827597, encodeId=d01f182e5971d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 14 16:54:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808468, encodeId=806b180846802, content=<a href='/topic/show?id=31f281840d6' target=_blank style='color:#2F92EE;'>#肢体残疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81840, encryptionId=31f281840d6, topicName=肢体残疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Sep 29 15:54:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836843, encodeId=d2dc183684321, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Fri Apr 11 12:54:00 CST 2014, time=2014-04-11, status=1, ipAttribution=)]
    2013-09-14 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1681253, encodeId=ead61681253f7, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Sep 22 00:54:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636719, encodeId=d3fb1636e191d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 14 21:54:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827597, encodeId=d01f182e5971d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 14 16:54:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808468, encodeId=806b180846802, content=<a href='/topic/show?id=31f281840d6' target=_blank style='color:#2F92EE;'>#肢体残疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81840, encryptionId=31f281840d6, topicName=肢体残疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Sep 29 15:54:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836843, encodeId=d2dc183684321, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Fri Apr 11 12:54:00 CST 2014, time=2014-04-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1681253, encodeId=ead61681253f7, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Sep 22 00:54:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636719, encodeId=d3fb1636e191d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 14 21:54:00 CST 2014, time=2014-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827597, encodeId=d01f182e5971d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 14 16:54:00 CST 2013, time=2013-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808468, encodeId=806b180846802, content=<a href='/topic/show?id=31f281840d6' target=_blank style='color:#2F92EE;'>#肢体残疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81840, encryptionId=31f281840d6, topicName=肢体残疾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Sep 29 15:54:00 CST 2013, time=2013-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836843, encodeId=d2dc183684321, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Fri Apr 11 12:54:00 CST 2014, time=2014-04-11, status=1, ipAttribution=)]

相关资讯

Lancet:空气污染致心衰住院和死亡增多

英国一项系统综述表明,空气污染可增加心衰所致住院和死亡,减轻污染则可预防心衰住院并节省大量医疗保健费用。论文7月9日在线发表于《柳叶刀》(Lancet)。 研究者对来自于12个国家的35项研究进行了分析,并评估了包括心衰在内的空气污染健康影响。 结果显示,在常见空气传播污染物中,一氧化碳与心衰所致住院或死亡增长程度最高具有相关性,但所有气体和颗粒空气污染物(臭氧除外)均与心衰住院或死亡

Lancet Neurol:脑白质病变程度重的颈动脉狭窄患者避免使用颈动脉支架置入

之前的随机试验已显示颈动脉支架植入术相比颈动脉内膜剥脱发生早期卒中的风险增加。来自英国伦敦的Jörg Ederle等医师研究验证了脑白质病变的程度是否影响颈动脉支架植入术与颈动脉内膜剥脱的围手术期卒中风险,在线发表在3013年7月12日的The Lancet Neurology杂志上,结果发现:脑白质的病变程度影响颈动脉支架植入术与颈动脉内膜剥脱术的围手术期卒中风险。该研究纳入对象为国际颈动脉支架

Lancet Oncol:肿瘤幸存者容易出现焦虑障碍

在过去的20多年中,肿瘤患者的生存预后得到改善,但是这种改善则会影响其罹患长期心境障碍的风险。来自英国Leicester伙伴关系信托的Alex J Mitchell等为了评估与健康对照或肿瘤幸存者的配偶进行比较时,肿瘤幸存者中抑郁和焦虑是否为常见的心境障碍,他们进行了系统综述和荟萃分析,并将其研究结果发表在Lancet Oncol 6月的在线期刊上。研究者系统检索了Medline、PsycINFO

Lancet Oncol:Niraparib治疗BRCA突变型散发肿瘤患者安全有效

ADP核糖聚合酶(PARP)在DNA修复和转录调节过程中起作用。Niraparib(MK4827)是一种口服的选择性PARP-1和PARP-2抑制剂,在缺乏BRCA和PTEN功能的基础肿瘤模型中可诱导致死性变化的产生。来自英国肿瘤研究结构的Shahneen K Sandhu等为了评估Niraparib的安全性、患者对治疗的耐受性、患者的最大耐受剂量、药代动力学和药效学特征,以及Niraparib的

Lancet:英国痴呆患病率在过去二十年明显降低

痴呆的流行是世界性难题之一。当今的痴呆患病情况是制定未来健康保健政策的依据,但现有的证据资料均年代久远。该研究旨在评价过去20年痴呆的最新流行病学资料。该研究采用相同的诊断标准和研究方法研究英国医学研究委员会认知功能与老龄化研究(MRC CFAS)的三项主要研究的原始资料。在1989年至1994年间,MRC CFAS研究者对英格兰和威尔斯6个不同地理区域年龄在65岁及以上人群做了基线研究访谈。对人

Lancet Oncol:空气污染会增高肺癌发病风险

近期,在《柳叶刀肿瘤学》上发表的一项研究的结果指出,即使空气污染的程度低于欧盟所规定的标准,长期暴露在这些特定的空气污染中仍然会增加肺癌(尤其是肺腺癌)的发生风险。 来自日本冈山大学环境和生命科学研究生院的Takashi Yorifuji 和广岛大学的Saori Kashima在述评中指出:“在现阶段,我们需要将空气污染(甚至是现阶段的浓度)列为肺癌的致病因素,并且我们也需要认识到空气污

Baidu
map
Baidu
map
Baidu
map